1. Home
  2. NDLS vs SCYX Comparison

NDLS vs SCYX Comparison

Compare NDLS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

HOLD

Current Price

$13.75

Market Cap

68.7M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.26

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
SCYX
Founded
1995
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
60.4M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
NDLS
SCYX
Price
$13.75
$4.26
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
28.8K
329.4K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
$495,089,000.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
0.37
N/A
52 Week Low
$0.47
$0.57
52 Week High
$13.95
$5.62

Technical Indicators

Market Signals
Indicator
NDLS
SCYX
Relative Strength Index (RSI) 63.74 72.96
Support Level $0.59 $0.67
Resistance Level $13.95 $5.62
Average True Range (ATR) 1.02 0.27
MACD 0.06 0.26
Stochastic Oscillator 90.15 73.19

Price Performance

Historical Comparison
NDLS
SCYX

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: